Telix Pharmaceuticals (ASX:TLX) named New York Stock Exchange-listed healthcare company Cardinal Health as one of the commercial radiopharmaceutical distributors of its prostate cancer imaging agent, Gozellix, according to a Tuesday statement.
Gozellix is slated for commercial launch in the first half of this year. The agreement will enable Cardinal Health to supply finished unit doses of Gozellix using Telix's Aartms Quantm Irradiation System cyclotron technology, per the statement.
The imaging agent received the US Food and Drug Administration's approval in March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.